Locally advanced breast cancer made amenable to radical surgery after a combination of systemic therapy and Mohs paste: two case reports

Journal of Medical Case Reports

Shozo Sasaki¹  Daisuke Matsui¹  Miki Matoba¹  Tatsuo Nakano¹  Tomoya Tsukada¹ 

[1] Department of Surgery, Asanogawa General Hospital, Kanazawa, Ishikawa 920-8621, Japan

关键词: Mohs surgery;    Modified radical mastectomy;    Breast cancer;   

Others  :  1195325
DOI  :  10.1186/1752-1947-6-360

 received in 2012-03-27, accepted in 2012-09-25,  发布年份 2012

【 摘 要 】

Introduction

Chemotherapy and other systemic therapies are the primary treatments for patients with unresectable, locally advanced breast cancer. The clinical application of supportive care using Mohs paste has become widespread for the purpose of improving patients’ quality of life. Here, we report two cases of locally advanced breast cancer, for which the patients underwent radical surgery after a combination of systemic therapy and Mohs chemosurgery.

Case presentations

Patient 1 was a 90-year-old Japanese woman with right breast cancer diagnosed as stage IIIB (T4bN1M0). The treatment included Mohs paste application and hormonal therapies. Patient 2 was a 60-year-old Japanese woman with right breast cancer diagnosed as stage IIIB (T4cN2aM0). Her treatment included Mohs paste application, together with chemotherapy (four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide, and four cycles of docetaxel). In both cases, a reduction in the primary tumor volume was observed, and radical mastectomy and axillary lymph node dissection were possible without relaxation incision or skin flap.

Conclusion

We report patients with no distant metastases who were able to undergo radical resection after a combination of systemic therapy and Mohs chemosurgery. For locally advanced breast cancer, Mohs chemosurgery, in addition to multidisciplinary treatment, is useful.

【 授权许可】

   
2012 Tsukada et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]NCCN Clinical Practice Guidelines in Oncology: Breast Cancer guideline–version 2. Washington, USA: National Comprehensive Cancer Network; 2011.
• [2]Schiech L: Malignant cutaneous wounds. Clin J Oncol Nurs 2002, 6:305-309.
• [3]McDonald A, Lesage P: Palliative management of pressure ulcers and malignant wounds in patients with advanced illness. J Palliat Med 2006, 9:285-295.
• [4]Maida V, Ennis M, Kuziemsky C, Trozzolo L: Symptoms associated with malignant wounds: a prospective case series. J Pain Symptom Manage 2009, 37:206-211.
• [5]Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW: Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol 2008, 9:1149-1156.
• [6]Skelton LA: The effective treatment of basal cell carcinoma. Br J Nurs 2009, 18:348-350.
• [7]Kakimoto M, Tokita H, Okamura T, Yoshino K: A chemical hemostatic technique for bleeding from malignant wounds. J Palliat Med 2010, 13:11-13.
• [8]Mohs FE, Sevringhaus EL, Schmidt ER: Conservative amputation of gangrenous parts by chemosurgery. Ann Surg 1941, 114:274-282.
• [9]Mohs FE: Chemosurgical treatment of tumors of the parotid gland: a microscopically controlled method of excision. Ann Surg 1949, 129:381-393.
• [10]Mohs FE: Chemosurgery. Clin Plast Surg 1980, 7:349-360.
• [11]Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
• [12]Dowsett C: Managing wound exudate: role of Versiva XC gelling foam dressing. Br J Nurs 2008, 17:S38-S40–42.
• [13]Parish LC, Dryjski M, Cadden S: Prospective clinical study of a new adhesive gelling foam dressing in pressure ulcers. Int Wound J 2008, 5:60-67.
• [14]Daniels S, Sibbald RG, Ennis W, Eager CA: Evaluation of a new composite dressing for the management of chronic leg ulcer wounds. J Wound Care 2002, 11:290-294.
• [15]Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R: Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005, 53:253-260.
• [16]Rowe DE, Carroll RJ, Day CL Jr: Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992, 26:976-990.